Our pilot data demonstrated that the majority of PrCa patients at UCH were diagnosed at an older age and had more aggressive clinical features (the median diagnostic PSA was 72.9 ng/ml, and 38% had a Gleason score of 8–10 tumor), in comparison to PrCa patients diagnosed in the US or other developed countries [2]. The gene discussed is KLK3; the disease is neoplasm.